CARTIHEAL Study Demonstrates Superior Pain Relief

Smith+Nephew disclosed further evidence from a multicenter, randomized controlled trial highlighting the clinical superiority of the CARTIHEAL AGILI-C Cartilage Repair Implant. The device resulted in higher overall Knee injury and Osteoarthritis Outcome Scores (KOOS) versus surgical standard of care (debridement or microfracture ) for all time points out to 60 months.

• Patients treated with the CARTIHEAL AGILI-C Implant reported significantly better knee pain relief, and quality of life improvements over a 5-year period.
• Patients treated with the CARTIHEAL Implant reported superior improvements in performing activities related to daily living, sport and recreation at 2, 4 and 5 years.
• Equal clinical outcomes were found in OA and non-OA patients receiving the CARTIHEAL Implant.

Smith+Nephew’s FDA-approved CARTIHEAL Implant recently received a Category I Current Procedural Terminology code for procedures that will go into effect on January 1, 2027.

The CARTIHEAL Implant is commercially available in the United States, including Puerto Rico. Composed of aragonite, the implant is able to repair cartilage and restore subchondral bone.

Source: Smith+Nephew